[PDF] Top 20 Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy
Has 10000 "Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy" found on our website. Below are the top 20 most common "Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy".
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy
... Plasma metabolome analysis. GC-MS analysis was performed with a GCMS-QP2010 Ultra (Shimadzu). The derivatized metabolites were separated on a DB-5 column (30 m × 0.25 mm inner diameter, film thick- ness 1.0 μm, Agilent ... See full document
19
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
... in combination with immunotherapy to elicit a response external to the radiation field ...the combination of nivolumab with radiation therapy in glioblastoma (NCT02617589) and advanced non-small cell ... See full document
21
Analysis of PD-1 related immune transcriptional profile in different cancer types
... of PD-1 blockade may not be enough to elicit an effective anti- tumor ...results, PD-1 was highly correlated with a diversity of immunomodu- ...salvage combination therapy to ... See full document
11
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 ...However, PD-1/PD-L1 checkpoint ... See full document
13
Cardiotoxicity of immune checkpoint inhibitors
... cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific ...therapies. Cancer immunotherapy with immune checkpoint ... See full document
12
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
... Combinational immunotherapy using anti- bodies to CTLA-4, PD-1/PD-L1, with small molecule inhibitors of indolamine deoxygenase (IDO), have also been shown to lead to improved tumor control and ... See full document
11
Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression
... cellular immunotherapy, cytokine therapy and so forth [1, 2]. The immune surveillance is stimulated by immunotherapy in cancer patients to make neoantigens be recognized and eradicated ... See full document
15
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
... diverse cancer in- dications ...VEGF blockade can enhance dendritic cell function and subsequent T cell activation ...ovarian cancer (EOC) ...of PD-1 and PD-L1, thus representing ... See full document
26
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
... of immunotherapy in cancer patients can be increased by testing patient’s tumors for their mutation and immune profiles, which would allow for the optimal design of a personalized treatment ... See full document
5
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
... induce host immune responses against cancer cells and may thus be viewed as a form of ...one immune-suppressive pathway may not be sufficient to eliminate ...the combination of ... See full document
13
The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018
... innate immune system can be subverted to promote the growth of cancer via tumor recruitment of suppressive myeloid cells which actively promote cancer, something that T cells do not ...breast ... See full document
12
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... tumor-derived PD-L1 by treating tumor bearing PD-L1 KO host with anti-PD-L1 antibodies [7, ...of PD-L1 blockade were not observed in tested tumor models (MC38, ID8 and B16-F10 ... See full document
8
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... of PD-1:PD-L1 blockade occurring outside of the tumor microenvironment due to heterogeneity of PD-L1 expression in cancer lesions, which is not always correctly assessed by core ... See full document
12
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
... within 1 – 42 days of chemoradiation over chemoradia- tion followed by placebo in locally advanced NSCLC ...and PD-L1 expression is likely to be at its ...the combination arm is due to the efficacy ... See full document
17
Failed immune responses across multiple pathologies share pan tumor and circulating lymphocytic targets
... of immune inference requires complex deconvolution (10), compli- cated by the influence of tumor expression programs on TILs ...by cancer heterogene- ity, and invasiveness and delays from surgical ... See full document
18
PD-1 blockade enhances the vaccination-induced immune response in glioma
... and PD-1 mAb were able to reject a second tumor inoculation without additional vaccination or PD-1 mAb ...of PD-1/PD-L1 to memory T cell generation in the tumor ... See full document
14
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
... and cancer subtypes ...for PD-L1 IHC testing in guidelines for use of immune checkpoint inhibitor therapy ...of PD-L1 is an inducible and dynamic biomarker which may indicate the relative ... See full document
13
Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
... on PD-L1 blockade monotherapy on December 19, ...receiving PD-L1 blockade monotherapy, the patient experienced unusually rapid disease progression demonstrated in repeated CT scans to rule out ... See full document
10
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
... models [36–41]. Thus, we queried whether a Class I se- lective HDACi drug (OKI-179) would augment the anti-tumor response in combination with nivolumab in the TNBC hu-CB-BRGS model. Interestingly, the combin- ... See full document
16
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
... DNA-damaging agents are mutagenic, as demonstrated by the increased risk of secondary cancers following treatment with radiotherapy or chemotherapeutics such as etoposide and also, by the mutational signatures associated ... See full document
41
Related subjects